Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Impact of an Early Palliative Approach (MAHO2)

15. mai 2019 oppdatert av: Hopital Foch

Impact of an Early and Collegial Consideration of Patients' Vulnerability Comparing to Usual Care. Cluster Randomized Control Study "Mort-A-l'Hôpital 2"

In 2003, MAHO study (Ferrand E, Jabre P, Vincent-Genod C, et al. Circumstances of death in hospitalized patients and nurses' perceptions: French multicenter Mort-a-l'Hôpital survey. Arch Intern Med. 2008 168: 867-875.) evaluated the way 3793 patients died in 200 French hospitals and showed that their conditions of death were not optimal. The 22th April 2005 French Law precised patient's end of life rights with necessity to refrain from any unreasonable obstinacy, the right to refuse treatments and the obligation of a collegial process decision when the patient is not conscious. Since then, studies haven't demonstrate any improvement and found that palliative strategy in France is much less used than in other developed countries.

Studieoversikt

Detaljert beskrivelse

In 2003, MAHO study evaluated the way 3793 patients died en 200 French hospitals and showed that their conditions of death were not optimal. The 22th April 2005 French Law precised patient's end of life rights with necessity to refrain from any unreasonable obstinacy, the right to refuse treatments and the obligation of a collegial process decision when the patient is not conscious. Since then, studies haven't demonstrate any improvement and found that palliative strategy in France is much less used than in other developed countries.

Principal Objective: To evaluate the impact of an early palliative strategy using vulnerability criteria compared to standard care.

Primary endpoint: Rate of withdraw/withhold of treatment in each group.

Secondary objectives: To evaluate the impact of early recognition of patients' vulnerability on death conditions ; to evaluate this strategy impact according to unit type on length of stay, palliative strategy modalities and caregivers' satisfaction.

Secondary endpoints: Rate of therapeutic involvement reflections ; rate of death following withholding or withdrawing of treatments ; traceability of the level of therapeutic involvement process ; Rate of patients deceased with their relatives next to them ; rate of patients deceased with comfort treatment ; rate of palliative care consultation before death ; rate of asks for euthanasia ; Doctor and nurse's perception of quality of support and death process of the patient

Methods: Prospective, controlled, cluster randomized study of routine care 2 groups:

  • Group A: standard care and practice after 1 day of training
  • Group B: 1 day of training, learning the vulnerability criteria that should induce early thinking about level of therapeutic involvement; web accessed forms will be available to help collegial process, withhold and withdraw decisions traceability, using legal requirements Number of patients to include: To detect a 20% absolute difference in palliative strategy used (30 to 50%), we determined that 5040 patients would provide a power of 80% with the use of a two-sided alpha level of 0.05. Sequential analysis is planned in order to early stop the study in case of efficacy or futility (minimal inclusion: 500 patients)

Inclusion criteria:

All patients hospitalized with at least one of the following vulnerability criteria will be included:

  • Evolutive and symptomatic incurable cancer
  • Aged more than 75 years old and presenting several geriatric syndromes (cognitive disorders, isolation, malnutrition, bedridden more than 12h per day)
  • Neurologic pathology, chronic, with loss of autonomy (Performance Status>3)
  • Final organ failure (heart, lungs, liver, kidney) with loss of autonomy (Performance Status>3)
  • Care refusal and/or expressed will to die or repeated request for help to die

Exclusion criteria:

  • Minors
  • Patients without indication for treatment or surveillance with length of stay inferior to 24h
  • Brain dead patients
  • Not consent patients

Duration: 37 months (28 inclusion months for each center and a follow-up to hospital discharge, death or 9 months if the patient is still hospitalized).

Number of participating centers: 20 centers (28 services) were selected and recruit after training program among centers that did not used a formalized process to initiate level of therapeutic involvement reflection.

Studietype

Intervensjonell

Registrering (Forventet)

1200

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Amiens, Frankrike, 80000
        • CHU
      • Antony, Frankrike, 92160
        • Hopital privé Oncologie Médicale
      • Antony, Frankrike, 92160
        • Hôpital Privé Medecine interne
      • Bobigny, Frankrike, 93000
        • Hopital Avicenne
      • Boulogne Billancourt, Frankrike, 92100
        • Hôpital Ambroise Paré
      • Champcueil, Frankrike, 91750
        • Hôpital Georges Clemenceau
      • Dijon, Frankrike, 21000
        • CHU
      • Epernay, Frankrike, 51200
        • Centre Hospitalier
      • Le Kremlin Bicetre, Frankrike, 94270
        • Hôpital Bicêtre
      • Lille, Frankrike, 59000
        • CHRU
      • Paris, Frankrike, 75010
        • Hopital Lariboisiere Medecine interne
      • Paris, Frankrike, 75014
        • Groupe Hospitalier Paris - Saint-Joseph
      • Paris, Frankrike, 75014
        • Hopital Cochin Gastro-Enterologie
      • Poitiers, Frankrike, 86000
        • Centre Hospitalier Universitaire
      • Roubaix, Frankrike, 59100
        • Centre Hospitalier
      • Soissons, Frankrike, 02200
        • Centre Hospitalier de Soissons
      • Suresnes, Frankrike, 92150
        • Hiopital Foch Néphrologie
      • Suresnes, Frankrike, 92150
        • Hopital Foch Cardiologie
      • Suresnes, Frankrike, 92150
        • Hopital Foch Chirurgie Urologique
      • Suresnes, Frankrike, 92150
        • Hopital Foch Médecine Interne
      • Suresnes, Frankrike, 92150
        • Hopital Foch Neurochirurgie
      • Suresnes, Frankrike, 92150
        • Hopîtal Foch Urgences
      • Valenciennes, Frankrike, 59300
        • CH

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Patient more than 18 years old hospitalized for at least 24h and who's prognosis (survival or quality of life) should lead to a palliative approach
  • Patient suffering with at least one of the following vulnerability criteria will be included:

    • Evolutive and symptomatic incurable cancer
    • Aged more than 75 years old and presenting several geriatric syndromes (cognitive disorders, isolation, malnutrition, bedridden more than 12h per day)
    • Neurologic pathology, chronic, with loss of autonomy (Performance Status>3)
    • Final organ failure (heart, lungs, liver, kidney) with loss of autonomy (Performance Status>3)
    • Care refusal and/or expressed will to die or repeated request for help to die
  • No opposition to the use of data collected from the patient or a relative or inclusion in emergency and non-opposition collected offline

Exclusion Criteria:

  • Minors
  • Patients without indication for treatment or surveillance with length of stay inferior to 24h
  • Brain dead patients
  • Not consent patients

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: Usual Practices
the centres applies their usual practices
Annen: Early consideration of vulnerability
Strategy promoting early consideration of patients' vulnerability
One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Rate of withdraw/withhold of treatment in each group
Tidsramme: From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital
To evaluate the impact of an early palliative strategy using vulnerability criteria compared to standard care.
From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Death conditions
Tidsramme: From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital

rate of death relied to a withholding/withdrawing treatment decision, rate relatives present at the time of death, rate of death with comfort drugs, rate of patient/family/relatives interview with a psychologist.

rate of death relied to a withholding/withdrawing treatment decision, rate relatives present at the time of death, rate of death with comfort drugs, rate of patient/family/relatives interview with a psychologist.

From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital
Early vulnerability consideration impact on length of stay
Tidsramme: From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital
total length of stay in the hospital
From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital
Palliative strategy modalities
Tidsramme: From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital
rate of reflections on level of therapeutic involvement
From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital
Early vulnerability consideration impact on caregivers' satisfaction
Tidsramme: From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital
Physician and nurses' perceptions about care management and conditions of death, caregivers interview with a psychologist
From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Edouard Ferrand, MD, e.ferrand@hopital-foch.org

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. november 2013

Primær fullføring (Faktiske)

1. mars 2019

Studiet fullført (Faktiske)

1. mars 2019

Datoer for studieregistrering

Først innsendt

17. februar 2016

Først innsendt som oppfylte QC-kriteriene

19. september 2016

Først lagt ut (Anslag)

20. september 2016

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. mai 2019

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. mai 2019

Sist bekreftet

1. mai 2019

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2013/99
  • 2012-A00444-39 (Annen identifikator: ANSM)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere